Patients with EGFR mutation‐positive NSCLC have been reported to benefit from EGFR tyrosine kinase inhibitors (TKIs),1,2 although some patients demonstrate a resistance to this treatment. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.